Emcure Pharmaceuticals Ltd Q1 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/uleluk8wo2f7dp3nqrpx28tz.pdf

Key Takeaways


India Business: Recovery and the Zuventus Turnaround

Satish Mehta: "I had made a very interesting statement, Alankar, there are 3 phases. First, I told you about stability, consolidation acceleration. These are the 3 very specific terms I used. So, as I told you in the last quarter, we had a problem. We had attrition as far as Zuventus is concerned. So now the stability has come back, normalization has taken place. consolidation has also happened and now we are moving towards acceleration."

International Business: The Growth Engine


Margins: Mix-Driven Compression and Expansion


Semaglutide: A Contested Opportunity

Satish Mehta: "I don't have a crystal ball here... the jury is out, wait for 3 to 6 months before we know what's really going on because I'm given to understand almost 40, 50 brands are being launched. At this stage, it is difficult to assess how much of this is channel stocking and how much represents actual consumption, so I would not like to hazard a guess."

Pipeline, Licensing and Structural Simplification

Satish Mehta: "I assure all of you that company strategy, operations, execution, everything remains unchanged."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growthLow to mid-teen; management more comfortable at the higher endFY27
EBITDA margin expansion70 to 100 bpsFY27
India organic growthAt par or faster than industry growthFull year FY27
India quarterly trajectoryNorthward movement quarter after quarter (Q2, Q3, Q4)FY27
ZuventusMoving from consolidation to acceleration phaseGoing forward
Gross marginAround 59% to 60%FY27
R&D spend4% to 5% of revenueFY27
Net debtIncrease to close to ~₹1,450 crore from what today I see at ₹1,560 crore reflecting Mantra and Gennova payoutsNext quarter (Q2 FY27)
Net cashTurn net cash positiveBy end of FY28
Semaglutide Canada filingFile in the current quarterNext few months

Key Metrics

MetricQ1 FY27
Revenue₹2,580 cr, +22.8% YoY
EBITDA₹508 cr, +25.8% YoY
EBITDA margin19.7%, +50 bps YoY
Profit after tax₹292 cr, +36.2% YoY
PAT marginimproved 110 bps YoY
Gross profit₹1,507 cr, +16.1% YoY
Gross margin58.4%, declined YoY; FY27 guidance ~59%
R&D spend₹90 cr, 3.5% of revenue; FY27 guidance 4%–5%
India business revenue₹1,095 cr, +10.2% YoY and +12% vs Q4 FY26
India organic growth~6%–7% (stripping Sanofi OAD and Roche)
International business revenue₹1,485 cr, +34.2% YoY
Europe revenue₹537 cr, +32.8% YoY
Canada revenue₹427 cr, +24.6% YoY
Rest of World revenue₹522 cr, +44.8% YoY
ARV share of ROW revenue~2/3 in Q1; full-year expected 50%–55%
Constant currency growth, international~12% (per an analyst's math)
Net debt₹1,103 cr as of June 30; expected ~₹1,450 cr next quarter
Gross debt₹1,291 cr as of June 30
Cash and equivalents₹189 cr as of June 30
Depreciation and amortization₹110 cr, up from ₹99 cr in Q1 FY26
Interest cost₹32 cr
Effective tax rate25.6%
Product approvals in quarter15-plus across developed and emerging markets
FY27 revenue growth guidancelow to mid-teen; management comfortable at higher end
FY27 EBITDA margin expansion guidance70–100 bps
Net cash expectedby end of FY28